Taro Pharmaceutical Industries Ltd.
283 articles about Taro Pharmaceutical Industries Ltd.
-
Taro Provides Results for December 31, 2023
1/25/2024
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and nine months ended December 31, 2023.
-
Taro to Release Third Quarter Results on January 25, 2024
1/19/2024
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the third quarter ended December 31, 2023, after the close of market on Thursday, January 25, 2024.
-
Nearly two decades in the making, the companies expect to close the deal in the first half of 2024, after which Taro Pharmaceutical will become a privately held entity and will no longer trade on the New York Stock Exchange.
-
Taro Announces Merger Agreement with Sun Pharma
1/17/2024
Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. announced that they have entered into a definitive merger agreement in which Sun Pharma, Taro's controlling shareholder, has agreed to acquire all of the outstanding ordinary shares of Taro other than the shares already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest.
-
Taro Provides Results for September 30, 2023
10/26/2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and six months ended September 30, 2023.
-
Taro to Release Second Quarter Results on October 26, 2023
10/19/2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023.
-
Taro Provides Results for the Quarter Ended June 30, 2023
7/27/2023
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter ended June 30, 2023.
-
Taro to Release First Quarter Results on July 26, 2023
7/19/2023
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the first quarter ended June 30, 2023, after the close of market on Wednesday, July 26, 2023.
-
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
6/30/2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com.
-
Taro Provides Results for Year Ended March 31, 2023
5/24/2023
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2023.
-
Taro to Release Full Year Results on May 23, 2023
5/18/2023
Taro Pharmaceutical Industries Ltd. announced that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023.
-
Taro Provides Results for December 31, 2022
1/24/2023
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and nine months ended December 31, 2022.
-
Taro to Release Third Quarter Results on January 24, 2023
1/19/2023
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023.
-
Taro Provides Results for September 30, 2022
10/27/2022
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and six months ended September 30, 2022.
-
Taro to Release Second Quarter Results on October 27, 2022
10/24/2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022.
-
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
8/16/2022
Intellipharmaceutics International Inc announced that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc., by which the Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory of Health Canada.
-
Taro Provides Results for the Quarter Ended June 30, 2022
7/27/2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2022.
-
Taro to Release First Quarter Results on July 27, 2022
7/26/2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022.
-
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
7/26/2022
Taro Pharmaceutical Industries Ltd. announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission, is available within the Investor Relations section of Taro’s website.
-
Taro Provides Results for the Year Ended March 31, 2022
5/27/2022
Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2022.